Multisite Pilot Study of Extended-Release Injectable Naltrexone Treatment for Previously Opioid-Dependent Parolees and Probationers

• NCJ Number: 239135
• Journal: Substance Abuse Volume: 33 Issue: 1 Dated: January-March 2012 Pages: 48-59
• Author(s): Donna M. Coviello, Ph.D.; James W. Cornish, M.D.; Kevin G. Lynch, Ph.D.; Tamara Y. Boney, M.S.; Cynthia A. Clark, M.s.n., Crnp, Aprn, Bc; Joshua D. Lee, M.D., M.SC.; Peter D. Friedmann, M.D., M.p.h.; Edward V. Nunes, M.D.; Timothy W. Kinlock, Ph.D.; Michael S. Gordon, D.p.a.; Robert P. Schwartz, M.D.; Elie S. Nuwayser, Ph.D.; Charles P. O'brien, M.D., Ph.D.
• Date Published: February 2012
• Length: 12 pages
• Grant Number(s): R01-DA-012268-05
• Sponsoring Agency: National Institute on Drug Abuse; Dana Foundation
• Publication Format: Article
• Publication Type: Report (Study/Research)
• Language: English
• Country: United States of America

Annotation

This study examined drug treatment options for opioid-dependent individuals.

Abstract

A feasibility study was conducted to pilot test the ability of five sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders. (Published Abstract)